hackint0sh/New-Dataset huggingface dataset:
nctId: NCT06377072 id: SHPL-W036-301 briefTitle: Efficacy and Safety of Shenqi Sherong Pill in Participants With Cervical Spondylotic Myelopathy overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-11 date: 2026-03 date: 2024-04-22 date: 2024-04-22 name: Shanghai Hutchison Pharmaceuticals Limited class: INDUSTRY briefSummary: The purpose of this study is to evaluate the efficacy and safety of Shenqi Sherong Pill in participants with Mild or Moderate Cervical Spondylotic Myelopathy (qi deficiency, blood stasis and kidney deficiency type) which based on placebo-control, providing a basis for drug registration. conditions: Cervical Spondylotic Myelopathy studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: INVESTIGATOR count: 428 type: ESTIMATED name: Shenqi Sherong Pill name: Placebo measure: Change in Modified Japanese Orthopaedic Association (mJOA) score measure: Change in mJOA score measure: Change in sensation of mJOA score measure: Changes in pain or stiffness score for neck and shoulder measure: Change in chest tightness score measure: Changes in hand and arm numbness scores measure: Change in numbness (or pain) scores from the chest to the toes measure: Change in Motor dysfunction of the upper extremities of mJOA score measure: Proportion of participants with at least 1 grade decline in Nurick grades measure: Change in Traditional Chinese medicine (TCM) syndrome integrality measure: Change in TCM syndrome score measure: Serious adverse events measure: Adverse events measure: Vital sign (systolic and diastolic blood pressure after 10-minute rest) measure: Vital sign (body temperature) measure: Vital sign (respiration) measure: Vital sign (heart rate） measure: Laboratory test indicator (blood routine) measure: Laboratory test indicator (liver function) measure: Laboratory test indicator (kidney function) measure: Laboratory test indicator (fasting glucose) measure: Laboratory test indicator (urine routine and urinary sediment count) measure: Laboratory test indicator (stool routine and occult blood) measure: Electrocardiogram(ECG) QT Interval measure: ECG QTc Interval measure: ECG QRS Interval measure: ECG PR Interval measure: Pathological sign (Hoffmann sign) measure: Pathological sign (Babinski sign) measure: Concomitant medication sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06377059 id: 2024-RH-phase1-WARD briefTitle: Early Detection of Complications During Immunotherapy for Haematological Malignancy overallStatus: NOT_YET_RECRUITING date: 2024-07-01 date: 2026-07-01 date: 2027-07-01 date: 2024-04-22 date: 2024-04-22 name: Rigshospitalet, Denmark class: OTHER briefSummary: Aims
* Expand the understanding of the interactions between physiology and immunology for the design of future projects and general knowledge Hypothesis Development of a risk model based on a combination of physiological and immunological parameters can contribute to early detection of patients at risk for clinical complications after anti-cancer treatment. conditions: Hematologic Cancer conditions: CRS - Cytokine Release Syndrome studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP primaryPurpose: DIAGNOSTIC masking: NONE count: 100 type: ESTIMATED name: WARD measure: CRS measure: Immune response measure: severe physiological deviations measure: clinical complications sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06377046 id: NL86643.068.24 briefTitle: Accelerated Pacing in Patients Undergoing Pace-and-ablate Strategy With LBBAP: a Randomized Controlled Pilot Trial acronym: PACE-AF overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2025-11 date: 2026-05 date: 2024-04-22 date: 2024-04-22 name: Maastricht University Medical Center class: OTHER briefSummary: The goal of this clinical trial is to determine the effect of accelerated pacing (pacemaker lower rate programmed to 80bpm) compared to pacing at the standard programmed lower rate of 60bpm in symptomatic atrial fibrillation patients undergoing pace-and-ablate strategy with LBBAP.
* echocardiographic measurements (LVEF, left ventricular ejection fraction; LVEDD, left ventricular end- diastolic diameter; LVESD, left ventricular end-systolic diameter; LAVI left atrial volume index; diastolic parameters; strain conditions: Atrial Fibrillation conditions: Permanent Atrial Fibrillation conditions: Persistent Atrial Fibrillation conditions: Pacemaker DDD conditions: Paroxysmal Atrial Fibrillation studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL interventionModelDescription: Randomized, single center, prospective, single blinded, parallel group, pilot-trial. primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 50 type: ESTIMATED name: Accelerated pacing name: Current standard of care measure: The effect of accelerated pacing (lower programmed rate of 80 bpm) compared to pacing at the standard programmed rate of 60 bpm on health-related quality of life (HRQoL) in symptomatic AF patients undergoing pace-and-ablate strategy with LBBAP. measure: The acute hemodynamic effects of different (accelerated) pacing rates on pulmonary capillary wedge pressure (PCWP). measure: The acute hemodynamic effects of different (accelerated) pacing rates on cardiac output (CO). measure: The acute hemodynamic effects of different (accelerated) pacing rates on arterial blood pressure. measure: The long-term effects of accelerated pacing on health-related quality of life based on the 36-item short form health survey (SF-36) among AF patients undergoing pace-and-ablate strategy. measure: The long-term effects of accelerated pacing on NTproBNP levels among AF patients undergoing pace-and-ablate strategy. measure: The long-term effects of accelerated pacing on device detected AF burden among AF patients undergoing pace-and-ablate strategy. measure: The long-term effects of accelerated pacing on device detected daily activity among AF patients undergoing pace-and-ablate strategy. measure: The long-term effects of accelerated pacing on echocardiographic changes among AF patients undergoing pace-and-ablate strategy. measure: The long-term effects of accelerated pacing on echocardiographic changes among AF patients undergoing pace-and-ablate strategy. measure: The long-term effects of accelerated pacing on echocardiographic changes among AF patients undergoing pace-and-ablate strategy. measure: The long-term effects of accelerated pacing on echocardiographic changes among AF patients undergoing pace-and-ablate strategy. measure: The long-term effects of accelerated pacing on echocardiographic changes among AF patients undergoing pace-and-ablate strategy. measure: Palpitations experienced as a result of (accelerated) pacing. sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06377033 id: 10877980 briefTitle: Using the EHR to Advance Genomic Medicine Across a Diverse Health System overallStatus: NOT_YET_RECRUITING date: 2024-05-01 date: 2026-12-31 date: 2027-06-30 date: 2024-04-22 date: 2024-04-22 name: University of Pennsylvania class: OTHER briefSummary: Given the expansion of indications for genetic testing and our understanding of conditions for which the results change medical management, it is imperative to consider novel ways to deliver care beyond the traditional genetic counseling visit, which are both amenable to large-scale implementation and sustainable. The investigators propose an entirely new approach for the implementation of genomic medicine, supported by the leadership of Penn Medicine, investigating the use of non-geneticist clinician and patient nudges in the delivery of genomic medicine through a pragmatic randomized clinical trial, addressing NHGRI priorities. Our application is highly conceptually and technically innovative, building upon expertise and infrastructure already in place.
Innovative qualities of our proposal include: 1) Cutting edge EHR infrastructure already built to support genomic medicine (e.g., partnering with multiple commercial genetic testing laboratories for direct test ordering and results reporting in the EHR); 2) Automated EHR-based direct ordering or referring by specialist clinicians (i.e., use of replicable modules that enable specialist clinicians to order genetic testing through Epic Smartsets, including all needed components, such as populated gene lists, smartphrases, genetic testing, informational websites and acknowledgement e-forms for patient signature); 3) EHR algorithms for accurate patient identification (i.e., electronic phenotype algorithms to identify eligible patients, none of which currently have phenotype algorithms present in PheKB; 4) Behavioral economics-informed implementation science methods: This trial will be the first to evaluate implementation strategies informed by behavioral economics, directed at clinicians and/or patients, for increasing the use of genetic testing; further it will be the first study in this area to test two forms of defaults as a potential local adaptation to facilitate implementation (ordering vs. referring); and 5) Dissemination: In addition to standard dissemination modalities,PheKB95, GitHub and Epic Community Library, the investigators propose to disseminate via AnVIL (NHGRI's Genomic Data Science Analysis, Visualization, and Informatics Lab-Space). Our results will represent an entirely new paradigm for the provision of genomic medicine for patients in whom the results of genetic testing change medical management. conditions: Genetic Predisposition conditions: Paraganglioma conditions: Pheochromocytoma conditions: ALS conditions: Parkinson Disease conditions: Polyneuropathies conditions: Frontotemporal Dementia conditions: Alzheimer Disease conditions: Cardiomyopathy Non-ischemic conditions: Thoracic Aortic Aneurysm studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: FACTORIAL primaryPurpose: HEALTH_SERVICES_RESEARCH masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1000 type: ESTIMATED name: Behavioral nudge measure: Rate of Genetic Testing measure: Rate of Genetic Test Orders/Referrals measure: Rate of Patient Engagement measure: Rate of Pathogenic variants and VUS measure: Rate of Clinician actions sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT hasResults: False
nctId: NCT06377020 id: 23-2490 briefTitle: Prevention and Choice for Type 2 acronym: PACT2 overallStatus: RECRUITING date: 2024-04-10 date: 2024-10-23 date: 2024-10-30 date: 2024-04-22 date: 2024-04-22 name: University of Colorado, Denver class: OTHER name: American Diabetes Association name: High Plains Research Network briefSummary: People living with prediabetes are advised to lose weight to prevent development of type 2 diabetes by participating in intensive lifestyle interventions (ILI's), such as PreventT2. The PreventT2 program focuses on a low-calorie diet for weight loss. However, many people find it difficult to stick to a low-calorie diet over the long-term. The identification of novel, effective and individualized dietary strategies to produce long-term weight loss is critically important in diabetes prevention. An ILI based on PreventT2 which considers individual preferences, allowing participants to choose among a variety of diets, may result in greater adherence to the diet than a standard PreventT2 intervention. ILIs also need to be available to individuals in a wide range of communities, including Americans living in rural communities, who experience higher rates of obesity and chronic disease, yet have less access to medical care, including programs for diabetes prevention. The investigators plan to develop and carry out a 16-week pilot and feasibility study of a group-based ILI program based on PreventT2 plus choice of dietary strategy (Prevention and Choice for Type2 , PACT2) delivered via videoconference to adults with prediabetes living in rural communities. Successful completion of this project will result in the refinement of an ILI that incorporates personal preferences and is tailored to individuals at high risk for type 2 diabetes living in rural areas where access to such interventions is limited. conditions: PreDiabetes studyType: INTERVENTIONAL phases: NA allocation: NA interventionModel: SINGLE_GROUP interventionModelDescription: This is a single group pilot and feasibility study primaryPurpose: TREATMENT masking: NONE count: 24 type: ESTIMATED name: PACT2 measure: Body weight measure: Blood pressure measure: Physical activity measure: Energy intake measure: HbA1c measure: 24 hr glucose levels measure: Dietary adherence sex: ALL minimumAge: 18 Years maximumAge: 75 Years stdAges: ADULT stdAges: OLDER_ADULT facility: University of Colorado Anschutz Medical Campus status: RECRUITING city: Aurora state: Colorado zip: 80045 country: United States name: Elizabeth Thomas, MD role: CONTACT phone: 303-808-2622 email: elizabeth.thomas@cuanschutz.edu lat: 39.72943 lon: -104.83192 hasResults: False
nctId: NCT06377007 id: WU66290 id: WU66290 type: OTHER_GRANT domain: Walailak individual grant briefTitle: Refractive Outcomes and Ocular Biometry of Two Swept-Source Optical Coherence Tomography-Based Biometers With Segmental or Equivalent Refractive Indices (ORION) acronym: ORION overallStatus: RECRUITING date: 2024-01-01 date: 2025-07-30 date: 2025-12-30 date: 2024-04-22 date: 2024-04-26 name: Walailak University class: OTHER briefSummary: Cataract surgery represents a common surgical intervention, encompassing the extraction of the opaque natural crystalline lens, followed by the substitution with an artificial intraocular lens (IOL). To ascertain an IOL possessing optimal power, antecedent to the surgery, preoperative evaluations are conducted through the utilization of a biometric devices. Diverse categories of these instruments are accessible, each harnessing distinct optical methodologies or mathematical algorithms to ascertain the most fitting IOL power. The principal objective of this study was to evaluate the ocular biometry and the predictive precision outcome of a biometer that uses standard keratometry to the prediction accuracy of another biometer that uses Total Keratometry. conditions: Cataract studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: OTHER masking: DOUBLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER count: 142 type: ESTIMATED name: IOLMaster 700 (Carl Zeiss Meditec AG) name: Argos (Alcon Laboratories, Inc.) measure: Mean absolute prediction error measure: Proportion of eyes with an absolute prediction error equal to or less than 0.25 sex: ALL minimumAge: 50 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Walailak University status: RECRUITING city: Nakhon Si Thammarat zip: 80160 country: Thailand name: Jakkrit.ju Juhong, MD. role: CONTACT phone: 0816773406 email: jakkrit.ju@wu.ac.th lat: 8.43333 lon: 99.96667 hasResults: False
nctId: NCT06376994 id: IRB00407311 id: 1U24HL169566-01 type: NIH link: https://reporter.nih.gov/quickSearch/1U24HL169566-01 briefTitle: Multi-Center Clean Air Randomized Controlled Trial in COPD acronym: Clean Air overallStatus: NOT_YET_RECRUITING date: 2024-09 date: 2027-09 date: 2028-09 date: 2024-04-22 date: 2024-04-22 name: JHSPH Center for Clinical Trials class: OTHER name: National Heart, Lung, and Blood Institute (NHLBI) briefSummary: This is a multi-center randomized, sham-controlled clinical trial to determine the effectiveness of an air cleaner intervention aimed at improving indoor air quality on reducing COPD exacerbation risk and improving quality of life, functional status, rescue medication use. conditions: Chronic Obstructive Pulmonary Disease (COPD) studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 770 type: ESTIMATED name: Air cleaner name: Sham air cleaner measure: St. George's Respiratory Questionnaire (SGRQ) sex: ALL minimumAge: 40 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Johns Hopkins city: Baltimore state: Maryland zip: 21224 country: United States name: Wendy Lorizio role: CONTACT phone: 410-510-2449 email: wlorizi1@jhmi.edu name: Maggie Maly role: CONTACT phone: 410-550-9527 email: mmaly1@jhmi.edu lat: 39.29038 lon: -76.61219 hasResults: False
nctId: NCT06376981 id: CHD23_0025 briefTitle: Hyaluronic Acid in Shoulder Tendinopathy acronym: ACCTE overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2026-08 date: 2026-11 date: 2024-04-22 date: 2024-04-22 name: Centre Hospitalier Departemental Vendee class: OTHER briefSummary: Multicentric, randomised study to compare the effectiveness on activity pain at 3 months of corticosteroid injection associated with hyaluronic acid with corticosteroids injection alone in patients with tendinopathy of the supraspinatus with clinical reevaluation at one, three and six months. conditions: Shoulder Tendinitis studyType: INTERVENTIONAL phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: DOUBLE whoMasked: PARTICIPANT whoMasked: OUTCOMES_ASSESSOR count: 132 type: ESTIMATED name: Hyaluronic acid injection name: Corticosteroid injection name: Placebo injection measure: Visual analog scale pain on activity ranging from 0 to 100 mm at month 3. sex: ALL minimumAge: 18 Years maximumAge: 65 Years stdAges: ADULT stdAges: OLDER_ADULT facility: CHD Vendée city: La Roche-sur-Yon country: France name: Céline COZIC, Dr role: PRINCIPAL_INVESTIGATOR lat: 46.66667 lon: -1.43333 facility: CHU Nantes city: Nantes country: France name: Christelle DARRIEUTORT-LAFFITE, Dr role: PRINCIPAL_INVESTIGATOR lat: 47.21725 lon: -1.55336 hasResults: False
nctId: NCT06376968 id: BA-G-H-1604 briefTitle: Prospective, Multicentre, Randomized, Controlled, Cross-over Study on the Safety and Performance of the Biologic Fusion Option of DialogiQ Compared to Haemodialysis Without Biologic Fusion in Hypotension Prone Patients on Maintenance Haemodialysis overallStatus: RECRUITING date: 2024-04-22 date: 2025-07 date: 2025-08 date: 2024-04-22 date: 2024-04-29 name: B.Braun Avitum AG class: INDUSTRY briefSummary: The goal of this prospective, randomized, controlled, cross-over, multicentric study is to demonstrate the safety of bioLogic Fusion in patients on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes. The main question it aims to answer is:
• Which is the number and percentage of individual sessions with reached prescribed post-dialysis body weight in the prescribed treatment time in each single session in hypotensive-prone patients on high-flux haemodialysis or hemodiafiltration within each patient with treatments performed with DialogiQ with (treatment A) or without (treatment B) the bioLogic Fusion option activated? Participants will in addition to their routine dialysis treatment undergo 2 physical examinations and regularly answer questionnaires.
A crossover design is used to compare treatments with or without the BioLogic Fusion function activated. conditions: Renal Dialysis studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER primaryPurpose: TREATMENT masking: NONE count: 56 type: ESTIMATED name: BioLogic Fusion measure: Post-dialysis body weight sex: ALL minimumAge: 18 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Policlinico S. Orsola - Malpighi - UOC Nefrologia, Dialisi e Ipertensione status: RECRUITING city: Bologna state: Emilia Romagna zip: 40138 country: Italy name: Annalisa Zucchelli, Prof. role: CONTACT name: Annalisa Zucchelli, Prof. role: PRINCIPAL_INVESTIGATOR lat: 44.49381 lon: 11.33875 hasResults: False
nctId: NCT06376955 id: IRB00014233-1 briefTitle: High Intensity Interval Versus Focused Ultrasound on Insulin Resistance in Diabetics With Abdominal Obesity acronym: diabetic overallStatus: NOT_YET_RECRUITING date: 2024-04-16 date: 2024-08-30 date: 2024-08-30 date: 2024-04-22 date: 2024-04-22 name: Badr University class: OTHER briefSummary: Obesity and diabetes share a common insulin resistance pathway and contribute to chronic hyperglycemia. Both high-intensity interval exercise (HIIE) and focused ultrasound (FUS) have been explored in the context of managing insulin resistance in diabetic individuals with abdominal obesity, though they operate through different mechanisms and have different implications. conditions: Insulin Resistance conditions: Abdominal Obesity conditions: Diabetes studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: TREATMENT masking: SINGLE whoMasked: PARTICIPANT count: 40 type: ESTIMATED name: High intensity interval exercise name: Focused ultrasound measure: Body mass index measure: Waist circumference measure: Skin fold measure: Value of HbA1c and HOMA-IR hormone sex: FEMALE minimumAge: 25 Years maximumAge: 35 Years stdAges: ADULT hasResults: False
nctId: NCT06376942 id: Int/IEC/2024/SPL-5 briefTitle: A RCT to Compare the Effectiveness of Nebulized Anticholinergics for Cough Suppression During Flexible Bronchoscopy acronym: NAFCOF overallStatus: NOT_YET_RECRUITING date: 2024-04-24 date: 2025-04-25 date: 2025-06-15 date: 2024-04-22 date: 2024-04-22 name: Post Graduate Institute of Medical Education and Research, Chandigarh class: OTHER briefSummary: No study has examined the role of inhaled glycopyrrolate on mucus secretion. We hypothesize that nebulized glycopyrrolate will improve bronchoscopy procedure by effectively suppressing airway mucus secretion, thereby decreasing cough, and thus improving patient comfort during bronchoscopy. In this study, we aim to compare the efficacy of nebulized glycopyrrolate versus nebulized ipratropium in suppression of cough during flexible bronchoscopy. conditions: Subjects Undergoing Flexible Bronchoscopy studyType: INTERVENTIONAL phases: PHASE2 phases: PHASE3 allocation: RANDOMIZED interventionModel: PARALLEL primaryPurpose: PREVENTION masking: QUADRUPLE whoMasked: PARTICIPANT whoMasked: CARE_PROVIDER whoMasked: INVESTIGATOR whoMasked: OUTCOMES_ASSESSOR count: 1050 type: ESTIMATED name: Glycopyrronium name: Ipratropium name: Saline measure: Cough count measure: Operator-estimated airway secretion measure: Operator-rated secretions on a visual analogue scale (VAS) measure: Operator-rated cough intensity on a visual analogue scale (VAS) measure: Patient-rated comfort on a visual analogue scale (VAS) measure: Adverse reactions sex: ALL minimumAge: 18 Years maximumAge: 85 Years stdAges: ADULT stdAges: OLDER_ADULT facility: Bronchoscopy suite, PGIMER city: Chandigarh zip: 160012 country: India lat: 30.73629 lon: 76.7884 hasResults: False
nctId: NCT06376929 id: oralcarbohydrateinpediatric briefTitle: Oral Carbohydrates in Pediatric Surgery and Random Blood Glucose Level overallStatus: NOT_YET_RECRUITING date: 2024-05 date: 2024-08 date: 2024-09 date: 2024-04-22 date: 2024-04-25 name: Cairo University class: OTHER briefSummary: The correlation between preoperative oral carbohydrate intake and intraoperative random blood sugar and also the effect on postoperative nausea and vomiting. conditions: Postoperative Nausea and Vomiting studyType: INTERVENTIONAL phases: NA allocation: RANDOMIZED interventionModel: CROSSOVER interventionModelDescription: randomized controlled primaryPurpose: SCREENING masking: NONE count: 120 type: ESTIMATED name: oral carbohydrate containing fluid measure: Mean values of Intraoperative random blood sugar in mg/dl sex: ALL minimumAge: 3 Years maximumAge: 9 Years stdAges: CHILD hasResults: False